Physician

Jeffrey J Kirshner, M.D.

According to 2025 Medicare claims, Jeffrey Kirshner, M.D. (NPI: 1447230420) practices hematology/oncology in the Syracuse, NY market, with the plurality of this provider's patient population coming from Onondaga, NY. This provider's primary affiliated billing organization is HEMATOLOGY-ONCOLOGY ASSOCIATES OF CNY, PC (NPI: 1902885429; TIN: 161184100) and primary practice location at 13057-9248. Kirshner is affiliated with the CoreHealth Alliance LLC (ACO ID: A5645), participating under the MSSP model.

Kirshner's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 640 traditional Medicare patients, billed 148,644 HCPCS/CPT codes, and received $2,734,662 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 429 prescription claims across 98 beneficiaries totaling $34,425 in drug costs, led by Xarelto (Rivaroxaban). DME data shows 45 claims. Open Payments data shows 17 records totaling $9,825. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $3,777,023 and ending at $2,734,662. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $207,670 and ending at $34,425. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,221	395,435	$3,777,023
2016	1,381	634,599	$6,496,427
2017	1,136	422,146	$4,526,849
2018	876	167,195	$2,076,904
2019	800	101,937	$1,668,344
2020	885	236,471	$3,701,863
2021	848	206,344	$3,191,157
2022	676	135,770	$2,039,162
2023	734	237,381	$3,776,478
2024	640	148,644	$2,734,662

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	101	367	$207,670
2016	119	498	$119,710
2017	126	531	$179,733
2018	106	474	$30,139
2019	102	408	$127,330
2020	101	354	$250,123
2021	115	443	$36,242
2022	109	405	$23,095
2023	102	340	$17,850
2024	98	429	$34,425

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	293	648	$35,220
2016	210	578	$9,320
2017	82	270	$7,225
2018	42	159	$7,987
2019	19	130	$7,847
2020	33	149	$3,045
2021	22	126	$1,335
2022	17	121	$2,128
2023	20	120	$3,522
2024	N/R	45	$374

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	157	329	$98
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	162	235	$93
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	139	158	$64
96375	Injection of additional new drug or substance into vein	114	616	$12
96372	Injection of drug or substance under skin or into muscle	126	225	$11

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xarelto	Rivaroxaban	12	600	$10,297
Anastrozole	Anastrozole	211	8,930	$2,112
Estradiol	Estradiol	12	448	$1,483
Tamoxifen Citrate	Tamoxifen Citrate	124	4,710	$1,266
Exemestane	Exemestane	18	720	$1,049

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	25	$314
Q0166	Granisetron hydrochloride, 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 24 hour dosage regimen	N	N/R	20	$60

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	0	$0	N/R
Research Payments	Reported research-related payment or transfer-of-value amount.	17	$9,825	PFIZER INC.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Jeffrey J. Kirshner, M.D.?

Tedicare shows public-source Medicare data for Jeffrey J. Kirshner, M.D. (NPI 1447230420), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Jeffrey J. Kirshner, M.D. have ACO affiliation data?

Jeffrey J. Kirshner, M.D. is shown with ACO affiliation data for CoreHealth Alliance LLC (MSSP, ACO ID A5645).

What billing organization is linked to Jeffrey J. Kirshner, M.D.?

Jeffrey J. Kirshner, M.D. is linked to HEMATOLOGY-ONCOLOGY ASSOCIATES OF CNY, PC (billing NPI 1902885429) in the available physician profile data.

Does Jeffrey J. Kirshner, M.D. have Open Payments data?

Jeffrey J. Kirshner, M.D. has 17 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.